Sales y derivados de API

<p>Applications Ramipril Methyl Ester is an impurity of Ramipril (R111000). Ramipril Impurity A.<br>References Eckert, H., et al.: Arzneim.-Forsch./Drug Res., 35, 1251 (1985), Aboul-Enein, H., et al.: Anal. Lett., 24, 2217 (1991), Bonazzi, D., et al.: J. Pharm. Biomed. Anal., 16, 431 (1997),<br></p>

<p>Applications 5-Chloro-2-thiophenecarboxylic Acid is a metabolite of Rivaroxaban (R538000).<br>References Brickner, S., et al.: J. Med. Chem., 39, 673 (1996), Sato, K., et al.: Eur. J. Pharmacol., 347, 231 (1998), Chang, P., et al.: IDrugs, 7, 50 (2004), Weinz, C., et al.: Drug Metab. Dispos., 37, 1056 (2009)<br></p>

<p>Applications Levosimendan Cyanoacetamide Hydrazone Impurity is an impurity of Levosimendan (L378000) which is a bioactive enantiomer of racemate, Simendan. It is a positive inotropic agent with vasodilating activity and also cardiotonic.<br>References Sandell, E.-P., et al.: J. Cardiovasc. Pharmacol., 26, S57 (1995); Pagel, P.S., et al.: Cardiovasc. Drug Rev., 14, 286 (1996)<br></p>

<p>Applications The active metabolite of Leflunomide, a potent disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis. LEF-M interferes with dendritic cell function.<br>References Kirsch, B.M., et al.: Arthritis Research and Therapy, 7, 3, R694, (2005)<br></p>

<p>Impurity Leflunomide EP Impurity H<br>Stability Hygroscopic<br>Applications 2-Cyano-N-[4-(trifluoromethyl)phenyl]acetamide (Leflunomide EP Impurity H) is used to prepare aminothiophene carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers. It is also used to synthesize (1,2,3-triazol-4-yl)benzenamines as inhibitors against VEGF receptors 1 and 2.<br>References Nikolakopoulos, G., et al.: Bioorg. Med. Chem., 14, 2358 (2006); Kiselyov, A., et al.: Bioorg. Med. Chem. Lett., 19, 1344 (2009)<br></p>

<p>Impurity Allopurinol EP Impurity E / Allopurinol USP Related Compound E<br>Applications 3-(Formylamino)-1H-pyrazole-4-carboxylic Acid Ethyl Ester (Allopurinol EP Impurity E) is an impurity of Allopurinol (A547300), a pyrazole derivative that has been shown to induce neoplasm immunogenicity.<br>References Nicolin, A. et al.: Cancer, Chemother. Rep., 57, 3 (1973); Bonmassar, E. et al.: Cancer Res., 35, 1957 (1975)<br></p>

<p>Stability Hygroscopic<br>Applications A drug used for the treatment of atrial fibrillation and atrial flutter in patients who have suffered cardiac arrhythmias.<br>References Singh, B., et al.: J. Cardiovas. Pharmacol., 52, 300 (2008), Hoy, S., et al.: Drugs, 69, 1647 (2009), Hohnloser, S., et al.: New Eng. J. Med., 360, 668 (2009),<br></p>

<p>Applications Riociguat is used in the treatment for pulmonary hypertension.<br>References Frey, R. et al.: J. Clin. Pharmacol., 51, 1051 (2011);<br></p>

<p>Applications Diclofenac-13C6 is a labelled analogue of Diclofenac Acid (D436465), which is a nonsteroidal anti-inflammatory compound and decycloxygenase (COX) inhibitor. Diclofenac-13C6 is also an intermediate in synthesizing Diclofenac-13C6 Sodium Salt (D436453), which is a labelled analogue of Diclofenac Sodium Salt (D436450).<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Yagi, K., et. al.: Biol. Pharm. Bull., 37, 1234 (2014); Kenny, J. R., et al.: J. Med. Chem., 47, 2816 (2004); Sasaki, A., et al.: J. Pharmacol. Sci., 108, 266 (2008); Dalvie, D., et al.: Chem. Res. Toxicol., 22, 357 (2009); Kenny, J. R., et al.: J. Med. Chem., 47, 2816 (2004), Sasaki, A., et al.: J. Pharmacol. Sci., 108, 266 (2008); Dalvie, D., et al.: Chem. Res. Toxicol., 22, 357 (2009)<br></p>

<p>Applications A labelled antihypertensive. An angiotensin converting enzyme (ACE) inhibitor, converted to active, diacid metabolite.<br>References Teetz, V., et al.: Arzneim.-Forsch., 34, 1399 (1984), Ruggenenti, P., et al.: Lancet, 352, (1998), Bosch, J., et al.: Br. Med. J., 324, 1 (2002),<br></p>

<p>Applications Febuxostat n-butyl Isomer is an impurity of Febuxostat (F229000) which is a xanthine oxidase/xanthine dehydrogenase inhibitor.<br>References Osada, Y., et al.: Eur. J. Pharmacol., 241, 183 (1993); Okamoto, K., et al.: J. Biol. Chem., 278, 1848 (2003); Mayer, M.D., et al.: Am. J. Therap., 12, 22 (2005); Tomlinson, B., et al.: Curr. Opin. Invest. Drugs, 6, 1168 (2005)<br></p>

<p>Applications 4-(3-Aminophenyl)-3-morpholinone is an intermediate during the preparation of imidazothiazoles as protein kinase inhibitors for treating cancers.<br>References Bamaung, N., et al.: PCT Int. Appl. (2009), WO 2009070516 A1 20090604.<br></p>

<p>Applications A metabolite of Rivaroxaban (R538000).<br>References Kubitza, D., et al.: Clin. Pharmacol. Ther., 78, 412 (2005), Roehrig, S., et al.: J. Med. Chem., 48, 5900 (2005), Biemond, B., et al.: Thromb. Haemost., 97, 471 (2007), Lang, D., et al.: Drug Metab. Dispos., 37, 1046 (2009),<br></p>

<p>Applications An antihypertensive. Angiotensin converting enzyme (ACE) inhibitor.<br>References Brown, N.L., et al.: Eur. J. Pharmacol., 148, 79 (1988), Kober, L., et al.: N. Engl. J. Med., 333, 1670 (1995), Malik, R.A., et al.: Lancet, 352, 1978 (1998)<br></p>

<p>Applications A labelled antihypertensive. An angiotensin converting enzyme (ACE) inhibitor, converted to active, diacid metabolite.<br>References Teetz, V., et al.: Arzneim.-Forsch., 34, 1399 (1984), Ruggenenti, P., et al.: Lancet, 352, (1998), Bosch, J., et al.: Br. Med. J., 324, 1 (2002),<br></p>

<p>Applications Riociguat-13C-d3 is the labelled analogue of Riociguat (R520000), which is used in the treatment for pulmonary hypertension.<br>References Frey, R. et al.: J. Clin. Pharmacol., 51, 1051 (2011);<br></p>

<p>Applications Methanamine Hydrochloride is used in the synthesis of betaine-homocysteine S-methyltransferase. Also used in the synthesis of novel oxazinones as polymerase inhibitors.<br>References Picha, J. et al.: Eur. J. Med. Chem., 65, 256 (2013); Gangloff, A. et al.: Bioorg. Med. Chem. Lett., 23, 4501 (2013);<br></p>

<p>Applications Nonionic, injectable radio-contrast medium. Diagnostic aid (radiopaque medium).<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Muetzel, W., et al.: Am.J. Neuroradiol., 4, 350 (1983), Dawson, P., et al.: Acta Radiol. Diagn., 25, 253 (1984),<br></p>

<p>Applications Sodium Chlorite is used as a bleaching agent for cotton textiles.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Shenai, V.A., Pai, S.M.: Textile Dyer Printer, 3, 153 (1969)<br></p>

<p>Applications An immunosuppressive. Inhibits T and B cell proliferation. Activity is attributed mainly to its metabolite, a malononitrile derivative, which is beleived to inhibit dihydroorotate dehydrogenase as well as several protein tyrosine kinases. Therapeutically as a antirheumatic (Merck Index).This compound is suitable for dihydroorotate dehydrogenase (DHODH) related research.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Vrenken, T., et al.: J. Hepatol., 49, 799 (2008), Mazzucco, G., et al.: Clin. Nephrol., 70, 163 (2008), Davies, M., et al.: J. Med. Chem., 52, 2683 (2009),<br></p>

<p>Applications Apixaban-d3 is labelled Apixaban (A726700) which is a potent, direct, selective, and orally active inhibitor of coagulation factor Xa. It is a potential new oral coagulant that may be useful prevention of venous thromboembolism in total hip, knee replacement orthopedic surgery and stroke in treatment of patient with venous thromboembolic disorder or with atrial fibrillation.<br>References Luettgen, J.M. et al.: J. Enz. Inhib. Med. Chem., 26, 514 (2011); Glanis, T. et al.: J. Thromb. Thrombol., 31, 310 (2011); barrett, Y.C. et al.: Thromb. Haemos., 105, 181 (2011);<br></p>

<p>Applications Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor.<br>References Ruff, C., et al.: Am. Heart J., 160, 635 (2010); Ogata, K., et al.: J. Clin. Pharm., 50, 73 (2010)<br></p>

<p>Applications Intermediate in the production of Deferasirox.<br></p>

<p>Applications Ethyl 2-(4-Hydroxyphenyl)-4-methylthiazole-5-carboxylate is used in the synthesis of the major metabolites of Febuxostat (F229000), a xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout. 40-120 mg/day febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout.<br>References Li, X., et. al.: Lett. Org. Chem., 12, 217 (2015); Vallu, V., et. al.: Anal. Chem. Indian J., 14, 339 (2014); Osada, Y., et al.: Eur. J. Pharmacol., 241, 183 (1993); Okamoto, K., et al.: J. Biol. Chem., 278, 1848 (2003); Mayer, M.D., et al.: Am. J. Therap., 12, 22 (2005); Tomlinson, B., et al.: Curr. Opin. Invest. Drugs, 6, 1168 (2005)<br></p>

<p>Stability Hygroscopic<br>Applications AR-C133913XX is an metabolte of Ticagrelor (T437700) which is the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Ticagrelor is used in the treatment of acute coronary syndromes (ACS).<br>References Matetzky, S., et al.: Circulation, 109, 3171 (2004); Bassand, J., et al.: Eur. Heart J., 28, 1598 (2007); Jakubowski, J., et al.: Cardiovasc. Drug Rev., 25, 357 (2007)<br></p>

<p>Applications An immunosuppressant that blocks T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially IL-2. Shown to inhibit the activity of FK-506 binding protein, thereby reversing its effects on sarcoplasmic reticulum Ca+2 release.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Asano, K., et al.: In Vivo, 10, 537 (1996), McCall, E., et al.: Circ. Res., 79, 1110 (1996), Raufman, J.P., et al.: J. Biol. Chem., 271, 19877 (1996), Rokaw, M.D., et al.: Am. J. Physiol., 271, C194 (1996), Knoll, G.A., and Bell, R.C.: Brit. Med. J., 318, 1104 (1999)<br></p>

<p>Applications Simendan is the racemic mixture of Levosimendan (L378000) which is a positive inotropic agent with vasodilating activity.<br>References Sandell, E.-P., et al.: J. Cardiovasc. Pharmacol., 26, S57 (1995); Pagel, P.S., et al.: Cardiovasc. Drug Rev., 14, 286 (1996)<br></p>

<p>Applications Repaglinide impurity.<br>References Grell, W., et al.: J. Med. Chem., 41, 5219 (1998),<br></p>